Publications by authors named "Martin Hoyle"

Claim this Profile
U
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia.
Qunfei Chen, Martin Hoyle, Varinder Jeet, Yuanyuan Gu, Kompal Sinha

Pharmacoeconomics· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee.
Zachary Tirrell, Alicia Norman, Martin Hoyle, Sean Lybrand, Bonny Parkinson

Pharmacoeconomics· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.
Shiraz Halloush, Nimer S Alkhatib, Abdulaali R Almutairi, Mathias Calamia, Hala Halawah, Martin Hoyle

Ann Pharmacother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis.
Varinder Jeet, Bonny Parkinson, Rachel Song, Rajan Sharma, Martin Hoyle

Semin Nucl Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microcosting Study of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Prostate Cancer.
Bonny Parkinson, Rajan Sharma, Varinder Jeet, Rachel Song, Martin Hoyle

Value Health Reg Issues· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
Rachel Song, Varinder Jeet, Rajan Sharma, Martin Hoyle, Bonny Parkinson

Pharmacoeconomics· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Irina A Tikhonova, Huiqin Yang, Segun Bello, Andrew Salmon, Sophie Robinson, Martin Hoyle

Health Technol Assess· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation.
Jo Varley-Campbell, Rubén Mújica-Mota, Helen Coelho, Neel Ocean, Max Barnish, Martin Hoyle

Health Technol Assess· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Martin Hoyle

Health Technol Assess· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Rumona Dickson, Angela Boland, Rui Duarte, Eleanor Kotas, Nerys Woolacott, Martin Hoyle

Appl Health Econ Health Policy· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Irina A Tikhonova, Nicola Huxley, Tristan Snowsill, Louise Crathorne, Jo Varley-Campbell, Martin Hoyle

Pharmacoeconomics· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal.
Irina A Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C Warren, Sophie Robinson, Martin Hoyle

Pharmacoeconomics· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Irina A Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C Warren, Sophie Robinson, Martin Hoyle

Pharmacoeconomics· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Martin Hoyle

Health Technol Assess· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Irina A Tikhonova, Martin W Hoyle, Tristan M Snowsill, Chris Cooper, Joanna L Varley-Campbell

Pharmacoeconomics· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Tracey Jones-Hughes, Tristan Snowsill, Marcela Haasova, Helen Coelho, Louise Crathorne, Martin Hoyle

Health Technol Assess· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle

Health Technol Assess· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.
Tristan Snowsill, Nicola Huxley, Martin Hoyle, Tracey Jones-Hughes, Helen Coelho

BMC Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
Tristan Snowsill, Nicola Huxley, Martin Hoyle, Tracey Jones-Hughes, Helen Coelho

Health Technol Assess· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence.
Ciani Oriana, Hoyle Martin, Pavey Toby, Cooper Chris, Garside Ruth

Value Health· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Martin Hoyle, Jaime Peters, Louise Crathorne, Tracey Jones-Hughes, Chris Cooper

Value Health· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of a cost-utility model of donepezil for Alzheimer's disease.
Jaime L Peters, Rob Anderson, Martin Hoyle, Chris Hyde

Int J Technol Assess Health Care· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
Christopher Hyde, Jaime Peters, Mary Bond, Gabriel Rogers, Martin Hoyle

Age Ageing· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Martin Hoyle, Gabriel Rogers, Tiffany Moxham, Zulian Liu, Ken Stein

Value Health· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved curve fits to summary survival data: application to economic evaluation of health technologies.
Martin W Hoyle, William Henley

BMC Med Res Methodol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis